Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 20 studies | 36% ± 19% | |
peripheral blood | 18 studies | 37% ± 15% | |
brain | 18 studies | 50% ± 22% | |
intestine | 10 studies | 25% ± 9% | |
kidney | 7 studies | 31% ± 16% | |
liver | 6 studies | 40% ± 22% | |
heart | 6 studies | 51% ± 19% | |
eye | 6 studies | 30% ± 10% | |
lymph node | 5 studies | 31% ± 14% | |
breast | 5 studies | 30% ± 14% | |
uterus | 4 studies | 28% ± 7% | |
prostate | 4 studies | 37% ± 24% | |
adipose | 4 studies | 49% ± 18% | |
pancreas | 3 studies | 45% ± 14% | |
bone marrow | 3 studies | 32% ± 13% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 5978.53 | 245 / 245 | 100% | 10.65 | 502 / 502 |
breast | 100% | 4505.08 | 459 / 459 | 100% | 7.34 | 1113 / 1118 |
thymus | 100% | 4344.87 | 651 / 653 | 100% | 6.16 | 604 / 605 |
uterus | 100% | 4192.15 | 170 / 170 | 99% | 4.29 | 453 / 459 |
bladder | 100% | 6196.00 | 21 / 21 | 98% | 4.57 | 496 / 504 |
esophagus | 100% | 7682.73 | 1445 / 1445 | 98% | 4.45 | 180 / 183 |
stomach | 100% | 4259.46 | 359 / 359 | 98% | 4.71 | 281 / 286 |
intestine | 100% | 6649.31 | 966 / 966 | 98% | 4.65 | 516 / 527 |
pancreas | 98% | 1886.60 | 322 / 328 | 99% | 5.70 | 177 / 178 |
lung | 100% | 5536.51 | 578 / 578 | 97% | 4.26 | 1115 / 1155 |
ovary | 100% | 5961.72 | 180 / 180 | 94% | 2.31 | 403 / 430 |
liver | 92% | 1597.81 | 207 / 226 | 98% | 3.39 | 396 / 406 |
kidney | 92% | 1633.16 | 82 / 89 | 92% | 2.76 | 831 / 901 |
brain | 90% | 2194.07 | 2385 / 2642 | 90% | 1.93 | 635 / 705 |
skin | 99% | 2674.33 | 1798 / 1809 | 68% | 1.59 | 321 / 472 |
adrenal gland | 67% | 823.36 | 174 / 258 | 84% | 1.73 | 194 / 230 |
adipose | 100% | 4584.40 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 7323.00 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 8.45 | 29 / 29 |
spleen | 100% | 3115.62 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 3.31 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 5.14 | 1 / 1 |
heart | 98% | 2006.07 | 840 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 79% | 2024.74 | 737 / 929 | 0% | 0 | 0 / 0 |
muscle | 67% | 1140.13 | 541 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 26% | 0.39 | 21 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0033574 | Biological process | response to testosterone |
GO_0010468 | Biological process | regulation of gene expression |
GO_0032680 | Biological process | regulation of tumor necrosis factor production |
GO_0042116 | Biological process | macrophage activation |
GO_0032655 | Biological process | regulation of interleukin-12 production |
GO_1900424 | Biological process | regulation of defense response to bacterium |
GO_1901509 | Biological process | regulation of endothelial tube morphogenesis |
GO_0042117 | Biological process | monocyte activation |
GO_0010629 | Biological process | negative regulation of gene expression |
GO_0030316 | Biological process | osteoclast differentiation |
GO_1901300 | Biological process | positive regulation of hydrogen peroxide-mediated programmed cell death |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0048661 | Biological process | positive regulation of smooth muscle cell proliferation |
GO_0010595 | Biological process | positive regulation of endothelial cell migration |
GO_0032745 | Biological process | positive regulation of interleukin-21 production |
GO_0006974 | Biological process | DNA damage response |
GO_0002903 | Biological process | negative regulation of B cell apoptotic process |
GO_2000341 | Biological process | regulation of chemokine (C-X-C motif) ligand 2 production |
GO_0050861 | Biological process | positive regulation of B cell receptor signaling pathway |
GO_0021756 | Biological process | striatum development |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0050727 | Biological process | regulation of inflammatory response |
GO_0042118 | Biological process | endothelial cell activation |
GO_1901256 | Biological process | regulation of macrophage colony-stimulating factor production |
GO_0061052 | Biological process | negative regulation of cell growth involved in cardiac muscle cell development |
GO_0071356 | Biological process | cellular response to tumor necrosis factor |
GO_0032651 | Biological process | regulation of interleukin-1 beta production |
GO_0061470 | Biological process | T follicular helper cell differentiation |
GO_0060766 | Biological process | negative regulation of androgen receptor signaling pathway |
GO_0045655 | Biological process | regulation of monocyte differentiation |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0036035 | Biological process | osteoclast development |
GO_0032496 | Biological process | response to lipopolysaccharide |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0001046 | Molecular function | core promoter sequence-specific DNA binding |
GO_0001227 | Molecular function | DNA-binding transcription repressor activity, RNA polymerase II-specific |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_1990837 | Molecular function | sequence-specific double-stranded DNA binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0050681 | Molecular function | nuclear androgen receptor binding |
GO_0005515 | Molecular function | protein binding |
Gene name | FOXP1 |
Protein name | Forkhead box protein P1 Forkhead box P1 12CC4 (Forkhead box P1, isoform CRA_a) Forkhead box protein P1 (Mac-1-regulated forkhead) (MFH) Forkhead box P1 (Forkhead box protein P1) FOXP1 protein |
Synonyms | hCG_1778483 HSPC215 |
Description | FUNCTION: Transcriptional repressor . Can act with CTBP1 to synergistically repress transcription but CTPBP1 is not essential (By similarity). Plays an important role in the specification and differentiation of lung epithelium. Acts cooperatively with FOXP4 to regulate lung secretory epithelial cell fate and regeneration by restricting the goblet cell lineage program; the function may involve regulation of AGR2. Essential transcriptional regulator of B-cell development. Involved in regulation of cardiac muscle cell proliferation. Involved in the columnar organization of spinal motor neurons. Promotes the formation of the lateral motor neuron column (LMC) and the preganglionic motor column (PGC) and is required for respective appropriate motor axon projections. The segment-appropriate generation of spinal cord motor columns requires cooperation with other Hox proteins. Can regulate PITX3 promoter activity; may promote midbrain identity in embryonic stem cell-derived dopamine neurons by regulating PITX3. Negatively regulates the differentiation of T follicular helper cells T(FH)s. Involved in maintenance of hair follicle stem cell quiescence; the function probably involves regulation of FGF18 (By similarity). Represses transcription of various pro-apoptotic genes and cooperates with NF-kappa B-signaling in promoting B-cell expansion by inhibition of caspase-dependent apoptosis . Binds to CSF1R promoter elements and is involved in regulation of monocyte differentiation and macrophage functions; repression of CSF1R in monocytes seems to involve NCOR2 as corepressor . Involved in endothelial cell proliferation, tube formation and migration indicative for a role in angiogenesis; the role in neovascularization seems to implicate suppression of SEMA5B . Can negatively regulate androgen receptor signaling . Acts as a transcriptional activator of the FBXL7 promoter; this activity is regulated by AURKA . .; FUNCTION: [Isoform 8]: Involved in transcriptional regulation in embryonic stem cells (ESCs). Stimulates expression of transcription factors that are required for pluripotency and decreases expression of differentiation-associated genes. Has distinct DNA-binding specifities as compared to the canonical form and preferentially binds DNA with the sequence 5'-CGATACAA-3' (or closely related sequences) . Promotes ESC self-renewal and pluripotency (By similarity). . |
Accessions | Q6IAJ1 ENST00000650188.1 A0A0B4J2F3 ENST00000491238.8 C9IYY1 ENST00000493089.7 [Q9H334-7] ENST00000648718.1 [Q9H334-7] A0A3B3IT14 A0A3B3IRW5 A0A3B3IS87 ENST00000650387.1 ENST00000648654.1 ENST00000318779.7 [Q9H334-5] ENST00000497553.4 ENST00000648321.1 ENST00000650068.2 [Q9H334-1] ENST00000650295.1 ENST00000648710.2 [Q9H334-7] A0A3B3ISQ7 ENST00000650402.1 ENST00000648895.1 ENST00000648426.1 [Q9H334-8] H0Y882 ENST00000485326.7 A0A3B3IST6 ENST00000484350.5 [Q9H334-6] ENST00000649631.1 [Q9H334-1] ENST00000648783.1 A0A3B3IT66 Q548T7 G5E965 ENST00000614176.5 ENST00000472382.7 A3KMG1 ENST00000650068 ENST00000648794.2 ENST00000649528.3 [Q9H334-1] ENST00000498215.7 [Q9H334-1] ENST00000475937.6 A0A3B3IST0 A0A087X2G3 Q9H334 ENST00000468577.6 A0A3B3IRL7 A0A3B3ITZ4 ENST00000649610.2 ENST00000318789.11 [Q9H334-1] ENST00000649592.1 A0A3B3IU15 ENST00000650156.1 ENST00000648748.3 ENST00000327590.9 A0A3B3IRS5 A0A3B3IU08 ENST00000649596.1 C9J5T4 A0A3B3ISA4 ENST00000497355.7 ENST00000471386.3 ENST00000648384.1 ENST00000648710 A0A3B3IT26 C9J0F0 A0A3B3IRY1 ENST00000647614.1 ENST00000649695.3 ENST00000649513.1 ENST00000649431.2 ENST00000648380.1 [Q9H334-1] A0A3B3IUB6 |